Experimental CAR t therapy takes aim at stubborn AL amyloidosis

NCT ID NCT07250269

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to other therapies. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to attack two specific targets on the abnormal cells causing the disease. The study will enroll 9 adults to check safety and see if the treatment can reduce signs of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GC012F (a dual-target CAR T cell therapy that attacks two proteins on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat AL amyloidosis, potentially controlling the disease and improving organ function.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it's too small to prove effectiveness. CAR T therapy can cause serious side effects like cytokine release syndrome, and the long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    RECRUITING

    Beijing, 100070, China

  • Research Site

    RECRUITING

    Beijing, CN-100730, China

  • Research Site

    RECRUITING

    Changchun, 130021, China

  • Research Site

    RECRUITING

    Guangzhou, 510100, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, 310003, China

  • Research Site

    RECRUITING

    Suzhou, 215006, China

  • Research Site

    RECRUITING

    Wenzhou, 325000, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430022, China